ALS Therapy Act Extended to 2031: New Safety Rules and 5-Year FDA Roadmap for Rare Diseases

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 pushes the expiration date of the current ALS research and grant programs from 2026 to 2031. Beyond just keeping the lights on, the bill tightens the screws on how the government monitors experimental drugs. It specifically requires the Secretary of Health and Human Services to look at actual safety and efficacy data—meaning how well the drug works and how safe it is—before renewing grants for investigational treatments. For a family dealing with an ALS diagnosis, this means the research being funded is under more rigorous, data-driven scrutiny to ensure it’s actually heading in the right direction.

Tightening the Safety Net

One of the most practical shifts in this bill is the new requirement for reporting safety issues. Under Section 3, any entity running a phase 3 clinical trial must immediately report serious adverse events or unexpected safety risks to the institution providing the grant. This isn't just a suggestion; it’s an additional layer of accountability on top of existing FDA rules (21 CFR 312.32). Think of it as a double-check system: if a trial drug causes an unforeseen problem, the information has to move fast. For a patient enrolled in a trial, this provision is designed to ensure that safety red flags don't get buried in bureaucratic paperwork.

Redefining the Fast Track

The bill also gets realistic about how modern drug trials actually work. It updates the definition of a "phase 3" trial to include combined phase 2/3 trials. In the world of medical research, these combined trials are often used to speed up the process by merging the safety-testing phase with the larger efficacy-testing phase. By officially recognizing these hybrid trials in the grant language, the bill ensures that researchers using modern, faster methods aren't locked out of federal funding just because they aren't following a traditional, slower three-step process.

The Five-Year Game Plan

Finally, the FDA is being put on a deadline to think long-term. Within 18 months of this bill becoming law, the FDA Commissioner must publish a specific five-year action plan on their website detailing how they will advance regulatory science and improve programs for rare neurodegenerative diseases. It’s not just a "post it and forget it" plan, either; at the five-year mark, the FDA has to publish a follow-up report showing exactly what they did and whether they actually met their goals. This creates a public receipt for the agency’s work, letting patients, doctors, and advocates see if the government is hitting its targets or just spinning its wheels.